Related Experiment Video
Updated: Jul 4, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Structural and Functional Disruption of Thiopurine S‑Methyltransferase by the A80P Variant: A Simulation and
Kaishiv Joshi1, Rahul Kumar2, Rakesh Kumar3
1Department of Human Genetics, Punjabi University, Patiala 147002, India.
The TPMT2 (A80P) genetic variant impairs thiopurine drug metabolism by affecting enzyme structure and cofactor binding. This variant was not found in northern Indian acute myeloid leukemia patients, highlighting the need for population-specific pharmacogenetic screening.
Area of Science:
- Pharmacogenetics
- Enzymology
- Computational Biology
Background:
- Thiopurine S-methyltransferase (TPMT) metabolizes thiopurine drugs.
- Genetic variations in TPMT can lead to adverse drug reactions.
- The TPMT2 (A80P) variant is suspected to impair enzyme function.
Purpose of the Study:
- To investigate the structural and functional impact of the TPMT2 (A80P) mutation.
- To determine the prevalence of the TPMT2 variant in acute myeloid leukemia (AML) patients from northern India.
Main Methods:
- Molecular dynamics simulations
- Molecular docking
- Umbrella sampling
- PCR-based genotyping
Main Results:
- The A80P mutation increases TPMT structural flexibility and reduces stability.
- The mutation weakens the binding of S-adenosylmethionine (SAM), compromising enzymatic function.
- The TPMT2 variant was absent in 50 AML patients and 50 healthy controls from northern India.
Conclusions:
- The TPMT2 (A80P) variant likely impairs TPMT enzymatic activity.
- Population-specific pharmacogenetic screening is crucial for personalized medicine.
- Tailoring genetic tests to local variant frequencies enhances cost-effectiveness and patient safety.
Related Concept Videos
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Pharmacogenomics: Identification of New Drug Targets
